Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Jan 2020 10:32

RNS Number : 8891Z
IXICO plc
15 January 2020
 

15 January 2020

 

IXICO plc

("IXICO" or the "Company")

 

Exercise of Options and PDMR Dealings

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it received notification on 10 January 2020 that John Hall, SVP Corporate Development and PDMR, exercised 75,000 options with an exercise price of 34p.

 

The Company has also received notification on 10 January 2020 that Robin Wolz, SVP Research & Development and PDMR, exercised 83,882 options of which 45,176 were exercisable at 30.5p and 38,706 were exercisable at 34p. The 83,882 shares were sold to a third party at an average price of 87.6p.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

John James Hall

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Corporate Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

34p

75,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

75,000 shares

- Price

34p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Robin Wolz

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

30.5p

45,176

 

 

34p

38,706

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

83,882 shares

- Price

32.1p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

 

Name

 

 

Robin Wolz

 

 

2

 

Reason for the notification

 

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

 

b)

 

Initial notification /Amendment

 

 

Initial notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

 

Name

 

 

IXICO plc

 

b)

 

LEI

 

 

2138005M1F59O6HWSA97

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

 

 

Identification code

GB00BCLY7L40

 

 

 

b)

 

Nature of the transaction

 

 

Sale

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) Date

Volume(s)

 

 

 

92p 10/1/20

18,395

 

 

 

90p 13/1/20

18,395

 

 

 

85p 13/1/20

47,092

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

83,882 shares

 

 

- Price

87.6p

 

 

e)

 

Date of the transaction

 

 

10/1/20 and 13/1/20

 

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur/Manel Mateus

ixico@optimumcomms.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBELFFBFLXBBB
Date   Source Headline
23rd Dec 20197:00 amRNSIXICO announces updates to client contracts
20th Dec 20197:00 amRNSStatement re Annual Report and Notice of AGM
9th Dec 20199:26 amRNSPDMR share sale
9th Dec 20197:02 amRNSHolding(s) in Company
9th Dec 20197:00 amRNSPDMR share purchase
5th Dec 20198:22 amRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSFinancial Results for the year ended 30 Sept 2019
2nd Dec 20197:00 amRNSIXICO to Present at Alzheimer's Disease Congress
22nd Nov 20197:00 amRNSNotice of Results
5th Nov 20199:00 amRNSIXICO to Present at HD and Ataxia Conferences
4th Nov 20192:51 pmRNSHolding(s) in Company
30th Oct 20199:00 amRNSIXICO to Present at 10th Annual CNS Summit 2019
28th Oct 20197:00 amRNSIXICO announces client contracts and appointed CBO
18th Oct 20197:00 amRNSHolding(s) in Company
15th Oct 20197:00 amRNSTrading Update for year ended 30 September 2019
11th Sep 20197:00 amRNSDirector/PDMR Shareholding
9th Sep 201911:48 amRNSHolding(s) in Company
9th Sep 201911:46 amRNSHolding(s) in Company
5th Sep 20193:43 pmRNSHolding(s) in Company
4th Sep 20195:07 pmRNSHolding(s) in Company
28th Aug 201912:21 pmRNSIssue of Equity
22nd Aug 20197:00 amRNSDirectorate Change
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.